avelumab (Bavencio)
Jump to navigation
Jump to search
Indications
- metastatic Merkel cell carcinoma
- advanced urothelial carcinoma with disease progression after platinum-based chemotherapy[4]
Dosage
- 10 mg/kg IV every 2 weeks
- continue until disease progression or unacceptable toxicity
Adverse effects
- most common
- fatigue, musculoskeletal pain
- diarrhea, nausea, decreased appetite
- infusion-related reactions, rash
- peripheral edema
- serious adverse effects
- immune-mediated effects.
- drug adverse effects of checkpoint inhibitor(s)
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
More general terms
References
- ↑ Bankhead C FDA Approves Drug for Rare Skin Cancer.
Avelumab active in Merkel cell carcinoma. MedPage Today. March 23, 2017 https://www.medpagetoday.com/Dermatology/SkinCancer/64096
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Kaufman HL, Russell J, Hamid O et al Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385. Epub 2016 Sep 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27592805 Free PMC Article
- ↑ Apolo AB, Infante JR, Balmanoukian A et al Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28375787 Free Article
- ↑ 4.0 4.1 Powles T et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020 Sep 18; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32945632 https://www.nejm.org/doi/10.1056/NEJMoa2002788